This is a working overview of reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
If impaired blood flow to the heart lasts long enough, it triggers a process called the ischemic cascade; the heart cells in the territory of the blocked coronary artery die (infarction), chiefly through necrosis, and do not grow back. A collagen scar forms in their place. When an artery is blocked, cells lack oxygen, needed to produce ATP in mitochondria. ATP is required for the maintenance of electrolyte balance, particularly through the Na/K ATPase. This leads to an ischemic cascade of intracellular changes, necrosis and apoptosis of affected cells. Cells in the area with the worst blood supply, just below the inner surface of the heart (endocardium), are most susceptible to damage. Ischemia first affects this region, the subendocardial region, and tissue begins to die within 15–30 minutes of loss of blood supply. The dead tissue is surrounded by a zone of potentially reversible ischemia that progresses to become a full-thickness transmural infarct. The initial "wave" of infarction can take place over 3–4 hours. These changes are seen on gross pathology and cannot be predicted by the presence or absence of Q waves on an ECG. The position, size and extent of an infarct depends on the affected artery, totality of the blockage, duration of the blockage, the presence of collateral blood vessels, oxygen demand, and success of interventional procedures. Tissue death and myocardial scarring alter the normal conduction pathways of the heart and weaken affected areas.
Excerpts appearing later that year on the Showtime cable network included a performance of "China Grove". The successful 1987 reunion sparked discussions about reconstituting the band on a permanent basis. They eventually decided to replicate the Toulouse Street/The Captain and Me incarnation, settling on a lineup featuring Johnston, Simmons, Hartman, Porter and Hossack, plus more recent addition LaKind, and released Cycles on Capitol Records in 1989. The album featured a Top 10 single, "The Doctor". The song is very similar to "China Grove", and the connection was further enhanced by guest Bill Payne's tinkling piano. Other material on the album included Johnston's "South of the Border", Dale Ockerman's and Pat Simmons' "Take Me to the Highway", and "I Can Read Your Mind", a version of the Isley Brothers' "Need a Little Taste of Love", and a version of the Four Tops classic, "One Chain (Don't Make No Prison)", which had been covered by Santana years before. Cycles proved a successful comeback album and was certified Gold. Bumpus participated in the 1989 and 1990 tours, adding his distinctive voice, keyboards, saxophone and flute. His presence bridged the gap between the current band and the McDonald era; he sang lead vocals on "One Step Closer" (as he originally had on the 1980 album) while Simmons took McDonald's part. The group was further augmented on the 1989 tour by Dale Ockerman (keyboards, guitar, backing vocals), Richard Bryant (percussion, vocals) and Jimi Fox (percussion, backing vocals).
=== Batteries === Due to their high energy density and the availability of sulfur, there is ongoing research in creating rechargeable lithium–sulfur batteries. Until now, carbonate electrolytes have caused failures in such batteries after a single cycle. In February 2022, researchers at Drexel University have not only created a prototypical battery that lasted 4000 recharge cycles, but also found the first monoclinic gamma sulfur that remained stable below 95 degrees Celsius.
The Pentagon was extensively damaged, causing one section of the building's E ring to collapse. The plane hit the Pentagon at the first-floor level. The front part of the fuselage disintegrated on impact; debris from the tail section penetrated the furthest into the building, breaking through 310 feet (94 m) of the three outermost of the building's five rings.
Sources: en.wikipedia.org
=== Pharmacokinetics === Flurpiridaz (18F) has peak blood radioactivity at 2.3 minutes after administration, followed by a rise and plateau. Distribution of this radiopharmaceutical is complex, as it transfuses into the liver (13%), kidneys (9%), brain (8%) and epicardium (3%, radioactivity retains for 1 hour after administration). Full clearance is achieved within 48 hours. Only metabolites of flurpiridaz are excreted, mainly in urine and feces. Flurpiridaz metabolises into many different polar metabolites. There are no differences in pharmacokinetics caused by age, sex, body mass index (BMI), diabetic status, Clid Pugh A hepatic impairment and renal impairment at eGFR≥19-89 mL/min.
=== Fictional characters === Television: Fat Albert, Eric Cartman, Peter Griffin, Homer Simpson Video games: Fat Princess, Rufus (Street Fighter) Other: Blob (Marvel Comics), Butterball Cenobite (comics & films)
The structure of somatostatin receptor antagonists is similar to that of the agonists. Some agonists were already approved by the FDA for clinical use, such as In-DTPA-octreotide and Ga-DOTATATE. Development started after the discovery of modifications that can be done to the octreotide group, an ssrt selective subtype agonist, to cause its agonistic effects to be lost and gain antagonistic effects. Different subtype receptor antagonists were later developed. Research has been done mostly on the sstr2 receptor antagonist, as the sstr2 receptor is expressed on most tumors. Somatostatin receptor antagonists are divided by generation based on the type of the subtype receptor antagonist. The first generation consists of sst2-ANT and BASS, which are sstr2 selective; and sst3-ODAN-8, which is selective for sstr3. After initial results of their increased sensitivity to neurocrine tumors appeared, ssrt2 selective antagonists that had even higher affinity were developed. These were LM3, JR10, and JR11, which make up the second generation. JR11 was shown to be the most effective among these 3 antagonists, and compounds that entered further clinical development to act as a PET imaging agent or therapeutic agent carried this subtype antagonist. The presence of a chelator coupled to the subtype antagonist was shown to affect the biological properties., by increasing the binding stability of the radionuclide to the rest of the compound, and increasing the binding affinity to the receptor by allowing conjugation of the radionuclide to the receptor.
The latest ONS data shows that inflation was 2.2% in August, unchanged from the previous month. The UK operator of TGI Fridays goes into administration, putting 4,500 jobs at risk. 19 September A BBC investigation, which includes testimony from over 20 female ex-employees, reveals serious sexual abuse allegations by the late former Harrods owner Mohamed Al-Fayed. The Bank of England holds interest rates at 5%. BBC News reports that a number of offenders released early from prison to ease overcrowding have yet to be fitted with electronic tags, despite this being a condition of their release. The Met Office issues a yellow warning for thunderstorms for 20 and 21 September following a period of unseasonably warm weather. The final edition of the London Evening Standard is published, before it switches to a weekly format titled The London Standard, published each Thursday from 26 September. 20 September The UK's debt-to-GDP reaches 100%, its highest level since 1961. A tornado strikes the Hampshire town of Aldershot, causing damage to properties and trees. The UK operation of the international construction company ISG collapses, with the loss of 2,200 jobs. Steven Wilson, who suffered life-changing injuries after being stabbed as he worked in a prison kitchen while serving a sentence for burglary, is awarded more than £5m in damages by the High Court. The UK government confirms that domestic abuse specialists will be "embedded" in emergency 999 call centres in England and Wales as part of plans to halve the number of incidents of violence against women and girls in ten years.
== External links == JPL Develops High-Speed Test to Improve Pathogen Decontamination at the Wayback Machine (archived 2016-03-04) at JPL. Spotting Spores at the Wayback Machine (archived 2016-03-04) at Astrobiology Magazine.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.